Physician profile
John E Harris
NPI 1902888720
$2,910.95
in general payments reported to CMS, 2019-2025
36 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $400 · 2021: $483 · 2022: $506 · 2023: $565 · 2024: $333 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $442.79 | 2019-2025 | Lokelma, Breztri, Farxiga |
| Abbvie INC. | $286.99 | 2021-2023 | |
| Novo Nordisk INC | $251.04 | 2019-2023 | Saxenda, Wegovy |
| Glaxosmithkline, LLC. | $182.30 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $182.24 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $175.93 | 2019-2021 | |
| Pfizer INC. | $174.06 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $172.74 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $125.91 | 2022-2024 | Austedo Xr, Ajovy, Austedo |
| Lilly USA, LLC | $101.74 | 2020-2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $91.78 | 2019-2021 | |
| Exact Sciences Corporation | $82.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $67.65 | 2023 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.21 | 2020-2022 | |
| Astellas Pharma US INC | $44.35 | 2023-2024 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $43.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.76 | 2022 | |
| Amgen INC. | $36.74 | 2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $33.05 | 2021 | |
| Eisai INC. | $30.75 | 2020 | |
| Horizon Therapeutics Plc | $26.86 | 2020 | |
| Sanofi Pasteur INC. | $25.83 | 2019-2020 | |
| Lundbeck LLC | $25.19 | 2023 | Rexulti |
| Allergan, INC. | $24.80 | 2020 | |
| Celgene Corporation | $23.82 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.71 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.37 | 2023 | Rexulti |
| Melinta Therapeutics, LLC | $18.61 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.78 | 2025 | Caplyta |
| Nevro Corp. | $16.36 | 2022 | |
| Shire North American Group INC | $16.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.65 | 2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $13.18 | 2022 | |
| Esperion Therapeutics, INC. | $12.13 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.67 | 2021 | |
| Sumitomo Pharma America, INC. | $11.26 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.